Form 4: 180 Life Sciences Director Ryan Lewis Smith Acquires 65,000 Shares of Common Stock

Director Ryan Lewis Smith acquired 65,000 shares of 180 Life Sciences Corp. common stock on February 20, 2025, as compensation for services rendered.

Summary

• On February 20, 2025, Ryan Lewis Smith, a director of 180 Life Sciences Corp., acquired 65,000 shares of common stock.
• The acquisition was made directly (D).
• The shares were issued as restricted stock subject to time-based vesting.
• Half of the shares will vest on July 1, 2025, and the remaining half on December 31, 2025, contingent upon continued service to the Issuer.
• The shares were issued in consideration for services rendered and to be rendered as a member of the Board of Directors.
• The issuance was made under the Issuer's 2022 Equity Compensation Plan.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. A director receiving stock as compensation is a normal business practice and indicates alignment with the company's success.

Positives

• The acquisition of shares by a director demonstrates confidence in the company's future.

Future Outlook

The director's continued service is tied to the vesting of the restricted stock, suggesting ongoing involvement with the company.

Industry Context

Director share acquisitions are common in the biotech industry as a form of compensation and alignment of interests.

Stakeholder Impact

• The acquisition of shares by a director can be viewed positively by shareholders as it aligns the director's interests with theirs.

Key Dates

Keywords

180 Life Sciences Corp, Ryan Lewis Smith, Director, Common Stock, Acquisition, Beneficial Ownership, SEC Form 4, Equity Compensation Plan, Vesting